



Annual General Meeting of the European Society of Gene & Cell Therapy

19th October 2018

SwissTech Convention Centre
(Lausanne, SWITZERLAND)

Agenda

- 1. ESGCT Board: nominations and elections**
- 2. Lausanne 2018: High level stats**
- 3. Financials: 2017 accounts**
- 4. ESGCT: Impact projects**
- 5. Future events**

Agenda

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



1. ESGCT Board: nominations and elections

RESULTS: elected members to the Board

Alessandro Aiuti

Giuliana Ferrari

Gloria Gonzalez Aseguinolaza

Zoltan Ivics

Axel Schambach


Juan Bueren has been elected as Vice-President to follow Hildegard Büning.

Agenda

2. Lausanne 2018: Stats

Registration stats

Total registrations:
1303





Travel Grant winners

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



TRAVEL GRANTS



P060: Thomas Hartjes

Dept. of Neurosurgery, Erasmus MC, Rotterdam
Organotypic multicellular spheres (OMS) as a 3D model system to study oncolytic adenovirus responses in glioblastoma tumours

P023: Katelyn Masiuk

Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA
dmPGE2 and poloxamer-F108 enhance transduction of human hematopoietic stem and progenitor cells with a β -globin lentiviral vector

P357: Sem Aronson

UMC University of Amsterdam
AAV-mediated liver directed gene therapy corrects the cholestatic phenotype in Abcb4^{-/-} mice

P298: Alessia De Caneva

ICGEB, Trieste
Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases

P396: Gabriele Ordazzo

San Raffaele Scientific Institute, Milan
Novel gene therapy approaches for whole brain delivery of the lysosomal GCse enzyme for wide protection from alpha-synuclein toxic aggregates

OR019: Anais Amaya

The University of Sydney, NSW
Successful *in vivo* editing of patient-derived primary human hepatocytes

P254: Valentina Vavassori

SR-TIGET, Milan
Optimization of a CRISPR/Cas9-based strategy for the correction of CD40LG gene in human haematopoietic stem cells and T cells

P255: Manel Llado

TIGEM, Naples
Homology-independent targeted integration for gene correction in photoreceptors



OR003: Micaela Harrasser

University College London
Effective targeting of ROR1+ solid tumours with next-generation Chimeric Antigen Receptor therapy

P483: Weiheng Su

University of Oxford
Exploiting adenovirus mechanisms for the enhanced production of AAV vectors



OR007: Kleopatra Rapti

Heidelberg University Hospital
Generation of novel immune-evading AAVs through identification and mutation of immunogenic epitopes in the variable capsid regions of adeno-associated Virus 9

P328: Razieh Monjezi

University Hospital Würzburg
CRISPR/Cas9 unites with Sleeping Beauty to generate CAR-T cells with enhanced therapeutic index for fighting against immunosuppressive tumour microenvironment



P052: Carlos Carrascoso

CIEMAT/CIBERER-ISCIII, Madrid
Towards the gene therapy of the bone marrow failure in patients with dyskeratosis congenita

P027: Yari Gimenez Martinez

CIEMAT/CIBERER-ISCIII, Madrid
Preclinical studies towards the gene therapy of Diamond-Blackfan anemia



P109: Marine Charrier

INRA/Oniris UMR 703, Nantes
Demonstration of immunomodulatory properties for human MuStem cell population, a promising candidate for cell therapy of muscular dystrophies

P435: Sarah Le Saux

Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-UM-ENSCM
Exploring the potential of extracellular vesicles as drug delivery systems



Programme Highlights

Award winners

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



ESGCT OUTSTANDING ACHIEVEMENT

INV029: Didier Trono (2018 Outstanding Achievement Award lecture)

EPFL, Lausanne

Retroelements, their polydactyl controllers and the specificity of human biology



**Human
Gene Therapy**
Mary Ann Liebert, Inc. publishers

ESGCT Young Investigator

OR031: Alessio Cantore (2018 Young Investigator Award lecture)

SR-TIGET, Milan

Shielding lentiviral vectors from phagocytosis increases hepatocyte gene transfer in non-human primates



AUDENTES

Agenda

3. Financials: 2017 accounts

Membership

	2013 Madrid with SETGYC	2014 The Hague with NVGCT	2015 Helsinki with FSGT	2016 Florence with ISSCR	2017 Berlin with DGGT	2018 Lausanne with ISSCR & SFTCG
TOTAL	462	422	528	961	977	1003
Academic	42%	43%	30%	55%	35%	45%
	194	181	158	529	342	452
Students	45%	45%	49%	20%	40%	28%
	208	190	259	192	391	280
Industry	13%	12%	21%	25%	25%	27%
	60	51	111	240	244	271

2017 accounts



Cash in bank 2016	€360,000
Revenue from Annual Congress 2017 (Berlin, Germany)	€90,000
Income membership 2017	€72,000
ESGCT Spring School	(€34,000)
Accounting and tax reporting	(€7,400)
Cashflow retainer for prepayments* and loss assurance	€400,000
Cash in bank for 2018 investment in Impact projects	€80,000

**Prepayments: venue and other deposits and outgoings (insurance) Annual Congress 2019, 2020, and Spring School 2019, 2020*

2017 investment: Students and ECR

Subsidised congress fee - students	€97,650
Free student membership	€11,700
Travel grants	€3,000
Full subsidy of Spring School	€34,000
Total investment in students and ECR	€146,350

Agenda

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



4. ESGCT: Impact initiatives 2019 and beyond

ESGCT priorities & goals

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



1. **PROMOTE** science and research in gene and cell therapy
2. **EDUCATE** through engagement activities
3. **EXCHANGE** of information & ideas
4. **ENCOURAGE** research & clinical application
5. **COLLABORATE** with other societies, organisations, and institutions

ESGCT Impact Initiatives

Students and Early Career Researchers

- Spring School
- Inter-lab bursary scheme
- Travel Grants
- Masterclasses - in person and online: presentation skills, abstract writing etc.

Stakeholders and Society

- Regulatory Roundtables
- Activity Heatmap of Europe
- Printable education packs for schools
- Blog and online forum

Supporting future leaders

A voice for gene and cell therapy in Europe

Supporting and promoting diversity

Sharing expertise and resources

ESGCT Partnerships

- ✓ **Supporting national societies:** meeting funding support, extending reach into national communities
- ✓ **International collaborations:** ISSCR, ASGCT, JSGCT
- ✓ **Human Gene Therapy:**
 - special rates for members
 - supporting European research
 - many ESGCT members are part of the editorial Board
 - opportunities for contributions from students and established researchers e.g. Vanessa Woods & Mark Brimble



NEXT

Annual General Meeting of the European Society of Gene & Cell Therapy

Friday 25th October 2019

**CCIB Convention Centre
(Barcelona, SPAIN)**